These observations support further studies with itopride in GERD. 
INTRODUCTION
Itopride is a novel prokinetic agent acting both as a dopamine D2 receptor antagonist and as an acetylcholine esterase inhibitor. Both animal (1) (2) (3) and human studies (5, 6) have shown the ability of the drug to accelerate delayed gastric emptying, associated with antiemetic properties. In a phase 2 controlled trial, itopride was superior to placebo in relieving symptoms of functional dyspepsia (6) . In a phase 3 program, this superiority was not confirmed, and comparison of both studies suggested that the presence of heartburn, which was excluded in the phase 3 program, was a predictor of response in the phase 2 studies (7). Heartburn is a typical symptom of gastro-esophageal reflux disease (GERD) (8) , and a pilot study in GERD patients confirmed the ability of itopride to decrease esophageal acid exposure (9) . The mechanisms underlying a potential beneficial effect of itopride in GERD remain to be elucidated.
The pathophysiology of GERD is multifactorial and involves several well-known mechanisms such as failure of the anti-reflux barrier, impaired esophageal clearance, the presence of caustic factors in the refluxate (acid and/or non-acid) and defective esophageal mucosal resistance (10) . The influence of itopride on the anti-reflux barrier has not been studied. Among the dysfunctions of the anti-reflux barrier, transient lower oesophageal sphincter relaxations (TLESRs) are the major mechanism underlying gastrooesophageal reflux events in normal subjects, and in the majority of GERD patients. The aim of the present study was to investigate the effect of itopride on oesophageal and lower oesophageal sphincter function in healthy subjects, with a focus on the occurrence of TLESRS. 
MATERIALS AND METHODS

Subjects
Studies were performed in 12 healthy volunteers (five men and seven women; mean age, 32.6±2.0 years; range, 23-41 years) with a mean body mass index of 22.2±0.9 kg/m 2 .
None of the subjects had symptoms or a history of gastrointestinal disease or upper gastrointestinal surgery, nor were they taking any medication. Written informed consent was obtained from each subject and the study protocol had been approved previously by the Ethics Committee of the University Hospital.
Study design
All subjects underwent the studies after 3 days premedication with itopride 50 mg, itopride 100mg or matching placebo t.i.d. in a double-blind randomised cross-over design.
Treatment periods occurred at least one week apart. On each day of measurements, subjects were studied after an overnight fast of at least 12 hours. A summary of the protocol is shown in Figure 1 . Together with a stationary manometry probe, a pH assembly was passed through the nose under topical anesthaesia and positioned with the pH electrode at 5 cm above the LES. After placement of the assembly, the subjects remained in a sitting position for a habituation period of 20 minutes. This period allowed baseline assessment of esophageal peristalsis and LES function. Ten wet swallows of 5 ml of water were administered at 1-minute interval and followed by ingestion of itoprode or placebo according to the double-blind, randomized cross-over design. During the 30 min after administration of the drug oesophageal and lower oesophageal sphincter pressure and oesophageal pH were continuously monitored. Sixty minutes after drug administration the subjects ingested a mixed liquid meal (400 mL, 600 kcal, 13% proteins, 48%
carbohydrates, 39% lipids; Nutridrink®, Nutricia, Bornem, Belgium) and recordings continued for 2 hours after the meal. Throughout the study, 10 wet swallows of 5 ml of water were administered at 30-minute intervals. Throughout the study, the sensations of 
Recording methods
Following an overnight fast, an oesophageal manometric catheter fitted with a 6-cm Dent Sleeve was introduced through the mouth. Subsequently, the oesophageal catheter was positioned so that pressures could be recorded from the gastric fundus (side hole 2 cm below the sleeve), the LES (sleeve), oesophageal body (side holes 4, 7 and 10 cm proximal to the sleeve) and pharynx (side hole 28 cm proximal to the sleeve, to detect swallows). The oesophageal catheter was infused at a flow rate of 0.5 mL/min with distilled water using a low-compliance pneumo-hydraulic capillary infusion system (Arndorfer Medical Specialties, Milwaukee, WI, USA). The infusion system was connected to external pressure transducers, and signals were recorded on a polygraph (Synectics Medical, Stockholm, Sweden).
The oesophageal pH was measured with an antimony pH electrode (Synectics Medical, Stockholm, Sweden) positioned 5 cm above the proximal margin of the sleeve. The pH electrode was calibrated in buffers of pH 1 and pH 7 before and after each study. During the study period, the oesophageal pH was recorded continuously using an ambulatory data-logger (MicroDigitrapper, Synectics Medical, Stockholm, Sweden).
Data analysis
Lower oesophageal motility
The basal lower oesophageal sphincter pressure was measured at end-expiration relative to the end-expiratory intra-gastric pressure. The basal lower oesophageal sphincter pressure was visually determined every 3 min and averaged over 30-min intervals. The influence of drug administration on the basal lower oesophageal sphincter pressure was assessed by comparing the value of the first with the value of the third pre-prandial 30-min interval. Transient lower oesophageal sphincter relaxations were defined according to published criteria (14) : (i) absence of a swallowing signal for 4 s before to 2 s after the onset of lower oesophageal sphincter relaxation; (ii) relaxation rate of ≥1 mmHg/s; (iii) time from onset to complete relaxation of ≤10 s; and (iv) nadir pressure of ≤2 mmHg. Excluding multiple swallows, lower oesophageal sphincter pressure falls that fulfil the last three criteria, but have a duration of >10 s, can also be classified as TLESRs irrespective of the timing of lower oesophageal sphincter relaxation relative to swallowing.
Oesophageal pH
The percentage of time with an oesophageal pH<4 and the number of acid reflux episodes were calculated. Acid reflux episodes were defined as a decrease in oesophageal pH to a value below pH 4 for at least 4 s or as a rapid drop of at least 1 pH unit if the pH was already below 4.
Statistical analysis
Based on previous studies, the study had an 85% power to detect 30% difference in TLESR rate at the 5% significance level. The changes in the basal LES pressure were evaluated using analysis of variance for repeated measures. The changes in TLESRs were analyzed using analysis of variance for repeated measures and Tukey-Kamer multiple comparisons post-test correction. P < 0.05 was considered to be statistically significant. Data are presented as the mean ± standard error of the mean (S.E.M.). 
RESULTS
Conduct of the study
The positioning of oesophageal manometry catheter and pH probe were all well tolerated, and all subjects completed the three sessions of studies as planned.
Lower esophageal sphincter pressure
Prior to drug administration, LES resting pressure and swallow-induced relaxations were similar for all 3 conditions (Table 1) (Table 1) .
Oesophageal motility
Both the amplitude or duration of peristaltic contractions were not significantly altered by both doses of itopride in the pre-prandial and post-prandial periods (Table 1) . Swallowinduced relaxations were not altered by either dose of itopride at any time point (Table 2) .
Swallowing rate
Both before and after the meal, the swallowing rate was significantly altered by itopride 100 mg. However, the 50 mg dose was associated with a significant rise in swallowing rate compared to placebo, both before and after the meal (Table 3) . 
Transient lower esophageal sphincter relaxations
The numbers of transient lower oesophageal sphincter relaxations after the administration of placebo and itopride are summarized in Figure 2 and Table 4 . After placebo, ingestion of the meal was associated with a significant increase in the rate of transient lower oesophageal sphincter relaxations during the first and the second post-prandial hour (ANOVA, p<0.001). After itopride 50 mg, no significant rise of TLESR rate was observed during the first postprandial hour (ANOVA, p>0.05), and in a paired comparison, the rate of TLESRs was significantly lower than after placebo during the first hour (t-test, p<0.05).
After itopride 100 mg, no significant rise of TLESR rate was seen during the first and the second postprandial hour (ANOVA, p>0.05), and the rate of TLESRs was significantly lower than after placebo during the second hour (t-test, p<0.05). The duration of TLESRS did not differ significantly between the treatment conditions (Table 3) .
Oesophageal pH monitoring
The percentage of time pH < 4 in the oesophagus did not differ between the itopride and placebo studies in the pre-prandial (0.3 ± 0.1%; 0.3 ± 0.2 % and 0.8 ± 0.5 %, for placebo, itopride 50 mg and itopride 100 mg respectively; NS) and postprandial periods (0.3 ± 0.1%; 0.4 ± 0.1 and 0.3 ± 0.2 %, for placebo, itopride 50 mg and itopride 100 mg respectively; NS).
The number of acid reflux episodes during the post-prandial period after itopride was not significantly different from that after placebo ( Figure 3 ). The number of acid reflux episodes was significantly increased postprandially in the placebo and itopride 100 mg groups, but not in the 50 mg group. Individual data showed a decrease in reflux episodes in all subjects after 100 mg, except for one subject who had a very high rate of reflux episodes under this dose. 
Symptoms and side effects
DISCUSSION
The analysis of phase 2 and phase 3 clinical trials with itopride in FD, as well as a small pH monitoring study in patients with heartburn suggested a beneficial effect of itopride in GERD (6, 7, 9) . In order to elucidate the underlying mechanism, we studied the influence of 2 doses of itopride in a double-blind placebo-controlled cross-over study on pre-and postprandial esopahgeal motility in healthy volunteers. Our main finding was that itopride inhibited the post-prandial increase in the rate of TLESRS without significantly affecting post-prandial LES pressure. Esophageal body peristalsis was also not altered by itopride.
Inhibition of TLESRS is a now well-established therapeutic target in GERD, and this effect may help to explain clinical effects of itopride on heartburn and on esophageal acid exposure (6, 7, 9) . On the other hand, itopride did not affect esophageal acid exposure in the present study, and the rise in postprandial acid reflux events was only significantly inhibited in the 50 mg group, with some evidence of large inter-individual variability in the 100 mg group. The lack of major effects on these reflux parameters is probably attributable to the fact that this study recruited healthy volunteers, and not GERD patients, and the relatively low sample size. Confirmation of these effects in a larger group of GERD patients seems warranted.
The mechanism underlying the inhibition of TLESRs by itopride remains to be established.
In the absence of effects on esophageal peristalsis and LES resting pressure, esophageal motility does not seem to be the target for itopride in TLESR inhibition. TLESRs are controlled by a vago-vagal reflex pathway which is triggered by gastric distention, TLESRs in the brainstem cannot be excluded, but is difficult to study in man. The effect of itopride on TLESRs seems to lack a clear dose-dependency. This could in part be due to some increased variability with the 100 mg dose, as illustrated in Figure 3 .
However, itopride has a dual pharmacological action as it acts both as a dopamine-2 receptor antagonist and as an acetylcholine esterase inhibitor. It is unclear which one of these pharmacological properties underlies the observed effect on TLESRs. The present study has a number of limitations. First, the number of reflux events and the number of TLESRs are generally low. This is probably attributable to the selection of asymptomatic healthy subjects with a normal body mass index, and the small size and caloric content of the meal. Second, the liquid meal may lead to more rapid buffering of intragastric acid, thereby under-estimating reflux events when pH monitoring is used.
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I think we need one figure showing the data for individuals -perhaps the total TSELRs for placebo and the 2 doses, with the data points joined... how consistent is the effect? I'd prefer this approach for the final figure -it tells the reader so much more than histograms.
We agree and added graphs with individual data Reviewer: 2 Comments for Transmission to the Authors The authors investigated the effects of the new prokinetic agent, itopride, on esophageal and LES function in healthy subjects. The study was conducted in a double blind crossover control trial with a one week washout period in normal volunteers. The authors show that this agent inhibits TLESRs but has little to no effect on esophageal peristalis or LES pressure. The experimental protocol is well described and the data is convincingly shown. The figure quality is poor and detracts from the relative importance of these findings.
As also pointed out by reviewer 3, Figure and Table 3 overlap. We have deleted Figure 3 and we have replaced it by individual numbers figures to better illustrate the effects of the drug.
The statistical analysis should be better described given the small sample size of ten subjects.
We have elaborated on power calculations and statistical analysis. We have now also added ANOVA with repeated measure analysis.
The major drawback from this study design is that the authors have selected normal volunteers to test this agent, however the authors recognize this relative weakness to the study design and have included this in the discussion section.
We agree and have included this in the discussion. (for your information: a patient study will start before the end of this year).
A proposed mechanism of action of the D2 antagonist/anticholinesterase would enhance the discusson section.
We have added a section on the relative contribution of both pharmacological mechanisms in the discussion section, highlighted in the revised version.
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-The liquid formula used is not an optimal meal: substantial intragastric acid buffering induced by this type of meal decreases occurrence of acid reflux, making it harder to see differences between different experimental conditions. Furthermore the postprandial rate of TLESRs is low even during placebo compared to similar studies in healthy volunteers. The authors should discuss these points.
We agree and this was addressed discussion section.
-a limitation of this study was that manometry and pH recording were performed with two independent systems, therefore analysis of motor events underlying reflux episodes could not be done. The authors should acknowledge this.
We agree and this was added to the discussion section.
-the rate of swallowing has been shown to be decreased by drugs affecting the rate of TLESRs. The authors should report the rate of spontaneous swallowinedg in order to better interpret the results.
We have added data on swallowing rate.
-BMI instead of body weight should be used This is corrected - Table 3 should be avoided
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